-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – JTE-451 in Allergies
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - JTE-451 in Allergies report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. JTE-451 in Allergies Drug Details: JTE-451 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Inavolisib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Inavolisib in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Inavolisib in Metastatic Breast Cancer Drug Details: Inavolisib (GDC-0077) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-548 in Radiculopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-548 in Radiculopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VX-548 in Radiculopathy Drug Details: VX-548 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-828 in Cystic Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-828 in Cystic Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VX-828 in Cystic Fibrosis Drug Details: VX-828 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-548 in Peripheral Neuropathic Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-548 in Peripheral Neuropathic Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VX-548 in Peripheral Neuropathic Pain Drug Details: VX-548 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dexamethasone Acetate in Ocular Pain (Eye Pain)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dexamethasone Acetate in Ocular Pain (Eye Pain) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dexamethasone Acetate in Ocular Pain (Eye Pain) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-548 in Post-Operative Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-548 in Post-Operative Pain report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VX-548 in Post-Operative Pain Drug Details: VX-548 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VX-548 in Diabetic Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VX-548 in Diabetic Peripheral Neuropathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VX-548 in Diabetic Peripheral Neuropathy Drug Details: VX-548 is under...
-
Product Insights
NewNet Present Value Model: AstraZeneca Plc’s Rilvegostomig
Empower your strategies with our Net Present Value Model: AstraZeneca Plc's Rilvegostomig report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Vertex Pharmaceuticals Inc’s Inaxaplin
Empower your strategies with our Net Present Value Model: Vertex Pharmaceuticals Inc's Inaxaplin report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.